Holen Sie sich die Stockscreener-App
22.35
0.72%
0.16
Handel nachbörslich:
22.35
Schlusskurs vom Vortag:
$22.19
Offen:
$22.38
24-Stunden-Volumen:
1.03M
Relative Volume:
0.58
Marktkapitalisierung:
$3.83B
Einnahmen:
$1.07B
Nettoeinkommen (Verlust:
$391.00M
KGV:
9.7666
EPS:
2.2884
Netto-Cashflow:
$6.31M
1W Leistung:
-1.41%
1M Leistung:
+0.68%
6M Leistung:
+0.09%
1J Leistung:
+47.62%
1-Tages-Spanne:
$22.12
$22.70
1-Wochen-Bereich:
$21.63
$22.73
52-Wochen-Spanne:
$14.45
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
22.35 | 3.80B | 1.07B | 391.00M | 6.31M | 2.2884 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-23 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
Acadia Pharmaceuticals officer Kihara sells $29,024 stock - Investing.com
Acadia Pharmaceuticals CFO Mark Schneyer sells $76,395 in stock - Investing.com
ACADIA PHARMACEUTICALS (NASDAQ: ACAD) officer sells shares for RSU tax withholding - Stock Titan
Acadia Pharmaceuticals (ACAD) CFO sells shares to cover RSU taxes - Stock Titan
FDA Approval for NUPLAZID issued to ACADIA PHARMS INC - Quantisnow
MSN Money - MSN
ACADIA Pharmaceuticals (ACAD) Q1 2026 Preview: EPS Est. $0.08, Reports May 6 - AlphaStreet
Acadia Pharmaceuticals appoints Jonathan M. Poole to board of directors - Investing.com
Acadia R&D Chief Plans Retirement As Company Stresses Pipeline Continuity - Sahm
BofA Securities Upgrades ACADIA Pharmaceuticals to Buy Rating - HarianBasis.co
ACADIA (ACAD) Upgraded to Buy After Recent Pullback - Insider Monkey
ACADIA Pharmaceuticals | 8-K: Current report - Moomoo
Acadia Pharmaceuticals Announces Retirement of Head of Research & Development, Ensures Continuity for Alzheimer’s and Lewy Body Dementia Clinical Trials - Minichart
Acadia Announces Planned Retirement of Head of R&D - TipRanks
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) - MSN
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career - BioSpace
Acadia Pharmaceuticals (NASDAQ: ACAD) details R&D head’s planned retirement and transition - Stock Titan
Pictet Asset Management Holding SA Buys 84,055 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
ACADIA Pharmaceuticals (ACAD) to Release Earnings on Wednesday - MarketBeat
Acadia Pharmaceuticals to Participate at Upcoming May 2026 Investor Conferences - BioSpace
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Yahoo Finance
ACADIA Pharmaceuticals | SCHEDULE 13G: Others - Moomoo
Vanguard files Schedule 13G: ACAD (NASDAQ: ACAD) 8.78M shares, 5.15% - Stock Titan
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Business Wire
Here's why Acadia Pharmaceuticals (ACAD) is a strong momentum stock - MSN
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - MSN
Axecap Investments LLC Has $3.65 Million Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA PHARMACEUTICALS INC ($ACAD) CEO 2025 Pay Revealed - Quiver Quantitative
ACADIA Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
ACADIA Pharmaceuticals Inc. (ACAD) PT Trimmed Slightly as RBC Flags Seasonal Biotech Headwinds - Insider Monkey
Acadia (NASDAQ: ACAD) plans 2026 virtual meeting, equity incentive share increase - Stock Titan
Acadia (ACAD) Stock: Is It Overpriced in Market | Q4 2025: Better Than ExpectedHot Market Picks - Cổng thông tin điện tử Tỉnh Sơn La
5 Most Undervalued Healthcare Stocks to Buy Now - Insider Monkey
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
(ACAD) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Assessing Acadia Pharmaceuticals (ACAD) Valuation After DAYBUE STIX Rollout And Upcoming Neurology Data Presentations - Sahm
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting - The National Law Review
BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $29 - Moomoo
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Update - MarketBeat
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - BioSpace
Acadia Pharmaceuticals to Report Q1 2026 Earnings on May 6 - National Today
How Investors Are Reacting To ACADIA Pharmaceuticals (ACAD) Expanding DAYBUE STIX Access for Rett Syndrome - Yahoo Finance
Press Release: Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - Moomoo
ACADIA Pharmaceuticals stock (US0042251084): Is the next product pipeline now the real test for sust - AD HOC NEWS
Acadia launches powder version of Rett syndrome treatment in the US - MSN
ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical - Yahoo
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):